SOST and hereditary disease: In this context, the putative inhibition of sclerostin represents a strategy to target bone remodeling unbalance in skeletal disorders, as osteoporosis, rheumatoid arthritis, bone related-genetic disorders, notwithstanding further studies are needed to better clarify how sclerostin-Ab modulates bone resorption since some authors reported the lack of modulation of RANKL, OPG, and other regulators of osteoclastogenesis during sclerostin-Ab treatment [80,81,82].